Lee’s Pharma Socazolimab Receives NMPA’s Breakthrough Therapy Designation for Treatment of Recurrent or Metastatic Cervical Cancer

February 10, 2021 Auto Bot Breakthrough Therapy Designation, NMPA, receives, Recurrent, regulatory 0

Shots:

  • NMPA has granted BTD to socazolimab for cervical cancer. Socazolimab is licensed from Sorrento to COF for the greater China territory
  • Lee intends to file an NDA to the NMPA and request a fast-track conditional approval of socazolimab to treat cervical cancer in Q2’21. Additionally, the companies are planning to expand their partnership for the license of additional therapeutic antibodies from Sorrento’s G-MAB library to treat hematologic and solid tumors
  • Socazolimab is a fully human anti-PD-L1 mAb and has demonstrated outstanding efficacy and safety profile in the clinical trials in cervical cancer patients

Click here ­to­ read full press release/ article | Ref: Sorrento | Image: News Medical

The post Lee’s Pharma Socazolimab Receives NMPA’s Breakthrough Therapy Designation for Treatment of Recurrent or Metastatic Cervical Cancer first appeared on PharmaShots.